- Home
- LESL vs AYTU Comparison
LESL vs AYTU Comparison
Compare LESL & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LESL | AYTU |
|---|---|---|
| Founded | 1963 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 23.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LESL | AYTU |
|---|---|---|
| Price | $1.83 | $2.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $18.14 | $9.33 |
| AVG Volume (30 Days) | ★ 261.4K | 141.4K |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,241,915,000.00 | $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.81 | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $0.95 |
| 52 Week High | $48.60 | $3.07 |
Technical Indicators
Market Signals| Indicator | LESL | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 66.44 |
| Support Level | $1.62 | $2.65 |
| Resistance Level | $1.99 | $3.07 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 34.13 | 69.93 |
Price Performance
Historical ComparisonAbout LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.